A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells
- 28 February 2010
- journal article
- Published by Elsevier BV in European Journal of Medicinal Chemistry
- Vol. 45 (2), 705-709
- https://doi.org/10.1016/j.ejmech.2009.11.017
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Adjuvant targeted therapy in early breast cancerCancer, 2009
- Chemoprevention of breast cancerAmerican Journal of Health-System Pharmacy, 2008
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsDrug Resistance Updates, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Recent advances in antimalarial drug developmentMedicinal Research Reviews, 2006
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997
- Akt Is a Direct Target of the Phosphatidylinositol 3-KinaseOnline Journal of Public Health Informatics, 1996
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cellsCell, 1989